MS4A1 and neoplasm: Interestingly, nivolumab-bound T cells had higher expression of MS4A1 than unbound T cells suggesting a mechanism for downregulation of CD20 in tumour-associated T cells is via the PD ligand 1-PD1 pathway [53].